Abstract
The spleen plays a paramount role in the host protection against invading microrganisms. In support of the above concept, in splenectomized patients there is increasing evidence of overwhelming postsplenectomy infections (OPSI). OPSI are caused by Streptococcus pneumoniae in about 80% of cases, but also Gram-negative bacteria are implicated in a certain number of cases. Therapeutically, penicillin and pneumococcal vaccines represent valid therapeutic approaches in Gram-positive OPSI. However, the effectiveness of polyvalent polysaccharide pneumococcal vaccines is still debated and, thus, other therapeutic strategies should be validated for combating OPSI. According to our personal data, a deficit of phagocytic activities and of T helper (h)-1 cells is very frequent in splenectomized patients. In sera, we found reduced levels of both Interferon-γ and Interleukin (IL)-4. These data are in accordance with the recent observation on the protective role of T cells against S. pneumoniae. In fact, patients deficient in IL-12 develop severe pneumococcal infections and undergo apoptosis of Th1 cells.
Keywords: lymphocytes, macrophages, spleen, t helper cells, vaccines
Current Pharmaceutical Design
Title: The Immunocompromised Host: Immune Alterations in Splenectomized Patients and Clinical Implications
Volume: 9 Issue: 24
Author(s): E. Jirillo, M. L. Mastronardi, M. Altamura, I. Munno, S. Miniello, G. Urgesi and L. Amati
Affiliation:
Keywords: lymphocytes, macrophages, spleen, t helper cells, vaccines
Abstract: The spleen plays a paramount role in the host protection against invading microrganisms. In support of the above concept, in splenectomized patients there is increasing evidence of overwhelming postsplenectomy infections (OPSI). OPSI are caused by Streptococcus pneumoniae in about 80% of cases, but also Gram-negative bacteria are implicated in a certain number of cases. Therapeutically, penicillin and pneumococcal vaccines represent valid therapeutic approaches in Gram-positive OPSI. However, the effectiveness of polyvalent polysaccharide pneumococcal vaccines is still debated and, thus, other therapeutic strategies should be validated for combating OPSI. According to our personal data, a deficit of phagocytic activities and of T helper (h)-1 cells is very frequent in splenectomized patients. In sera, we found reduced levels of both Interferon-γ and Interleukin (IL)-4. These data are in accordance with the recent observation on the protective role of T cells against S. pneumoniae. In fact, patients deficient in IL-12 develop severe pneumococcal infections and undergo apoptosis of Th1 cells.
Export Options
About this article
Cite this article as:
Jirillo E., Mastronardi L. M., Altamura M., Munno I., Miniello S., Urgesi G. and Amati L., The Immunocompromised Host: Immune Alterations in Splenectomized Patients and Clinical Implications, Current Pharmaceutical Design 2003; 9 (24) . https://dx.doi.org/10.2174/1381612033454306
DOI https://dx.doi.org/10.2174/1381612033454306 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bridge Between Neuroimmunity and Traumatic Brain Injury
Current Pharmaceutical Design Group A Streptococcal Infections in Children
Current Pediatric Reviews Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Microemulsion and Microemulsion-Based Gels for Topical Antifungal Therapy with Phytochemicals
Current Pharmaceutical Design High-Level Expression and Purification of an Analgesic Peptide from Buthus martensii Karch
Protein & Peptide Letters Activin and TGF-β Effects on Brain Development and Neural Stem Cells
CNS & Neurological Disorders - Drug Targets Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology The Role of Immune System in Schizophrenia
Current Immunology Reviews (Discontinued) Heat Shock Protein Inhibitors for the Treatment of Fungal Infections
Recent Patents on Anti-Infective Drug Discovery Ectopic ATP Synthase in Endothelial Cells: A Novel Cardiovascular Therapeutic Target
Current Pharmaceutical Design Current Advances in the Identification and Characterization of Putative Drug and Vaccine Targets in the Bacterial Genomes
Current Topics in Medicinal Chemistry Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Cefepime and its Role in Pediatric Infections
Recent Patents on Anti-Infective Drug Discovery New Strategies and Patent Therapeutics in EBV-Associated Diseases
Mini-Reviews in Medicinal Chemistry Role of Dietary Polyphenols in Attenuating Brain Edema and Cell Swelling in Cerebral Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Development of Aminoglycoside Antibiotics Effective Against Resistant Bacterial Strains
Current Topics in Medicinal Chemistry Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Intravenous Immunoglobulin (IVIG) in Rheumatologic Diseases: A Review of its Mechanism of Action
Current Rheumatology Reviews Cisternal Sustained Release Dihydropyridines for Subarachnoid Hemorrhage
Current Neurovascular Research Intravenous Immunoglobulin Preparations and Autoimmune Disorders: Mechanisms of Action
Current Pharmaceutical Biotechnology